Oregon Public Employees Retirement Fund grew its holdings in shares of Cambrex Co. (NYSE:CBM) by 1.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 12,997 shares of the biotechnology company’s stock after acquiring an additional 235 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Cambrex were worth $505,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. BlackRock Inc. boosted its position in Cambrex by 3.2% during the 4th quarter. BlackRock Inc. now owns 4,885,273 shares of the biotechnology company’s stock worth $184,469,000 after acquiring an additional 153,664 shares during the period. Bank of New York Mellon Corp boosted its position in Cambrex by 10.2% during the 4th quarter. Bank of New York Mellon Corp now owns 1,654,842 shares of the biotechnology company’s stock worth $62,487,000 after acquiring an additional 153,406 shares during the period. Mackenzie Financial Corp boosted its position in Cambrex by 41.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,487,875 shares of the biotechnology company’s stock worth $56,182,000 after acquiring an additional 434,406 shares during the period. Tributary Capital Management LLC boosted its position in Cambrex by 25.0% during the 1st quarter. Tributary Capital Management LLC now owns 359,150 shares of the biotechnology company’s stock worth $13,953,000 after acquiring an additional 71,868 shares during the period. Finally, Geode Capital Management LLC boosted its position in Cambrex by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 353,011 shares of the biotechnology company’s stock worth $13,329,000 after acquiring an additional 26,856 shares during the period.

Shares of Cambrex stock opened at $39.58 on Tuesday. The company has a quick ratio of 2.01, a current ratio of 2.96 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $1.34 billion, a PE ratio of 14.29, a PEG ratio of 3.11 and a beta of 2.32. Cambrex Co. has a fifty-two week low of $33.80 and a fifty-two week high of $69.43.

Cambrex (NYSE:CBM) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported $0.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.10. The business had revenue of $159.46 million during the quarter, compared to analyst estimates of $159.71 million. Cambrex had a return on equity of 12.25% and a net margin of 14.35%. The company’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.72 earnings per share. Equities analysts anticipate that Cambrex Co. will post 1.28 earnings per share for the current fiscal year.

Several analysts have recently weighed in on the company. Zacks Investment Research upgraded Cambrex from a “hold” rating to a “strong-buy” rating and set a $52.00 price objective for the company in a report on Friday, May 10th. First Analysis lowered Cambrex from a “strong-buy” rating to an “outperform” rating and upped their price objective for the company from $45.00 to $55.00 in a report on Tuesday, May 7th. ValuEngine upgraded Cambrex from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Robert W. Baird lowered Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 price objective for the company. in a report on Friday, May 3rd. They noted that the move was a valuation call. Finally, Jefferies Financial Group lowered Cambrex from a “buy” rating to a “hold” rating and set a $43.00 price objective for the company. in a report on Friday, February 22nd. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $47.80.

ILLEGAL ACTIVITY WARNING: “Oregon Public Employees Retirement Fund Has $505,000 Holdings in Cambrex Co. (CBM)” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/oregon-public-employees-retirement-fund-has-505000-holdings-in-cambrex-co-cbm/3031113.html.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Featured Story: What is required to own or exchange cryptocurrency?

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.